Clinical Trial Update: Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating radiation therapy with durvalumab, with or without tremelimumab, for bladder cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Terence Friedlander, MD | Conditions: Bladder Cancer | Phase 2 | Status: WITHDRAWN